Results 11 to 20 of about 40,704 (273)

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

Frontiers in Pharmacology, 2023
Introduction: Pharmacogenetics-informed drug prescribing is increasingly applied in clinical practice. Typically, drug metabolizing phenotypes are determined based on genetic test results, whereupon dosage or drugs are adjusted. Drug-drug-interactions (DDIs) caused by concomitant medication can however cause mismatches between predicted and observed ...
Laura M. de Jong, Soukayna Boussallami, Elena Sánchez-López, Martin Giera, Maarten E. Tushuizen, Menno Hoekstra, Lukas J. A. C. Hawinkels, Robert Rissmann, Robert Rissmann, Robert Rissmann, Jesse J. Swen, Martijn L. Manson   +11 more
doaj   +8 more sources

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse

Scientific Reports, 2021
CYP2C19*2 and CYP2C19*17 might influence tamoxifen metabolism and clinical outcome. Our aim was to investigate the effect of CYP2C19 genotypes on tamoxifen concentrations and metabolic ratios (MRs) and breast cancer recurrence in a large cohort of ...
A. B. Sanchez-Spitman, J. J. Swen, V. O. Dezentjé, D. J. A. R. Moes, H. Gelderblom, H. J. Guchelaar   +5 more
doaj   +2 more sources

Genetic polymorphism of cytochrome p450 (2C19) enzyme in Iranian Turkman ethnic group [PDF]

Oman Medical Journal, 2013
Objective: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study
Ataby, O.A., Mansourian, A.R., Marjani, A., Samai, N.M., Tabari, R.G.   +4 more
core   +4 more sources

Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population

Scientific Reports, 2021
Prior knowledge of allele frequencies of cytochrome P450 polymorphisms in a population is crucial for the revision and optimization of existing medication choices and doses.
Rattanaporn Sukprasong, Sumonrat Chuwongwattana, Napatrupron Koomdee, Thawinee Jantararoungtong, Santirhat Prommas, Pimonpan Jinda, Jiratha Rachanakul, Nutthan Nuntharadthanaphong, Nutcha Jongjitsook, Apichaya Puangpetch, Chonlaphat Sukasem   +10 more
doaj   +2 more sources

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update [PDF]

Clinical pharmacology and therapy, 2017
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline,
Bishop, Jeffrey R., Caudle, Kelly E., Dunnenberger, Henry M., Ellingrod, Vicki L., Gaedigk, Andrea, Hicks, J. Kevin, Kharasch, Evan D., Klein, Teri E., Müller, Daniel J., Sangkuhl, Katrin, Shimoda, Kazutaka, Skaar, Todd C., Stingl, Julia C., Swen, Jesse J.   +13 more
core   +2 more sources

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [PDF]

Clinical pharmacology and therapy, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
Bishop, Jeffrey R., Caudle, Kelly E., Chiulli, Dana L., Gaedigk, Andrea, Graham, Rebecca L., Hicks, J. Kevin, Ji, Yuan, Klein, Teri E., Leckband, Susan G., Leeder, J. Steven, LLerena, Adrián, Müller, Daniel J, Sangkuhl, Katrin, Scott, Stuart A., Skaar, Todd C., Stingl, Julia C.   +15 more
core   +2 more sources

<p>The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia</p>

Neuropsychiatric Disease and Treatment, 2020
Clozapine (CLZ) is the gold standard drug for treatment-refractory schizophrenia (TRS). However, approximately 30% of patients partially respond to CLZ, defining this subset with super refractory schizophrenia (SRS). Alterations in enzyme activity may affect CLZ responses; the CYP3A4, CYP1A2 and CYP2C19 genes are primarily responsible for CLZ ...
Martha Sosa-Macías, Hiasmin Franciely da Silva Neri, Rosana Pereira Vianello, Agostinho Tavares Semedo, Carlos Galaviz-Hernández, Rodrigo Bernini de Brito, Rodrigo Bernini de Brito, Christielly Rodrigues-Silva, Paulo César Ghedini   +8 more
openaire   +5 more sources

The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors [PDF]

Indonesian Biomedical Journal, 2014
BACKGROUND: Cytochrome P450 (CYP) enzymes play important roles in human, including drug metabolism. CYP2 is the largest family of human CYP, with its sequence comprising almost one third of all CYP sequences, and responsible for the metabolism of ...
Muliaty, D. (Dewi), Yusmiati, Y. (Yusmiati)   +1 more
core   +6 more sources

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention [PDF]

JACC: Cardiovascular Interventions, 2018
OBJECTIVES: This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI).
Alestock, Tameka D., Alsip, Jorge, Anderson, R. David, Ardati, Amer K., Beitelshees, Amber L., Brott, Brigitta C., Brown, Lawrence, Cavallari, Larisa H., Chumnumwat, Supatat, Clare-Salzler, Michael J., Coons, James C., Cooper-DeHoff, Rhonda M., Dave, Chintan V., Denny, Joshua C., Dillon, Chrisly, Duarte, Julio D., Elsey, Amanda R., Empey, Philip E., Gong, Yan, Hamadeh, Issam, Harada, Shuko, Hillegass, William B., Hines, Lindsay, Horenstein, Richard B., Howell, Lucius A., Jeng, Linda J.B., Johnson, Julie A., Kelemen, Mark D., Kimmel, Stephen E., Kreutz, Rolf P., Lee, Craig R., Lee, Y.M., Limdi, Nita A., Magvanjav, Oyunbileg, McDonough, Caitrin W., Montasser, May, Nelson, David R., Nutescu, Edith A., Nwaba, Devon C., Pakyz, Ruth E., Palmer, Kathleen, Peterson, Josh F., Pollin, Toni I., Pratt, Victoria M., Quinn, Alison H., Robinson, Shawn W., Schub, Jamie, Shuldiner, Alan R., Skaar, Todd C., Smith, Donald M., Sriramoju, Vindhya B., Starostik, Petr, Stevenson, James M., Stouffer, George A., Stys, Tomasz P., Varunok, Nicholas, Vesely, Mark R., Voora, Deepak, Wake, Dyson T., Weck, Karen E., Weitzel, Kristin W., Wilke, Russell A., Willig, James, Winterstein, Almut G., Zhao, Richard Y.   +64 more
core   +2 more sources

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole

Clinical and Translational Science
AbstractVoriconazole is the cornerstone of the treatment and prevention of fungal infections. While there is a good correlation between CYP2C19 genotype and voriconazole exposure during prophylactic treatment, no correlation was found in patients with invasive aspergillosis. Proinflammatory cytokines result in inhibition of CYP2C19 enzyme activity (and
Sylvia D. Klomp, Anette Veringa, Jan‐Willem C. Alffenaar, Mark G. J. de Boer, Lambert F. R. Span, Henk‐Jan Guchelaar, Jesse J. Swen   +6 more
openaire   +5 more sources